Wells Fargo Adjusts Price Target on Sangamo Therapeutics to $2 From $3, Keeps Equalweight Rating
Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Super Micro, Nvidia, Broadcom, Tesla, MicroStrategy, Sangamo, and More Stock Market Movers
CompoSecure, Cemtrex And 3 Stocks To Watch Heading Into Tuesday
Truist Financial Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $7
Barclays Maintains Sangamo Therapeutics(SGMO.US) With Buy Rating, Maintains Target Price $9
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}